<DOC>
	<DOC>NCT02547454</DOC>
	<brief_summary>This observational trial will examine the efficacy and safety of Mircera for renal anemia in participants with stage III-IV CKD in daily clinical practice. Mircera will be prescribed by treating physician and followed for approximately 36 months.</brief_summary>
	<brief_title>An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Participants aged &gt; 18 years with CKD Participants who are eligible for Mircera treatment according to current guidelines and summary of product characteristics (SmPC) Nonrenal anemia Pregnancy and breastfeeding Uncontrolled hypertension Known hypersensitivity to methoxy polyethylene glycolepoetin beta Administration of any other study drug within 30 days prior to study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>